[Alpha Tau in GlobeNewswire] Alpha Tau announces robust long-term safety and efficacy data from multiple clinical trials of Alpha DaRT

JERUSALEM, Aug. 17, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today initial long-term safety and tumor control outcomes for patients with unresectable, recurrent, or locally advanced head and neck or skin tumors treated Alpha DaRT across four prospective trials conducted at several international institutions.

Read more here.